News

Top Penny Stocks to Buy Now? 3 to Watch in July

  • Check these three penny stocks out for your watchlist right now The post Top Penny Stocks to Buy Now? 3 to Watch in July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
    07/15/2022

Check These Penny Stocks For Your Watchlist This Week

  • Can these penny stocks climb this week? The post Check These Penny Stocks For Your Watchlist This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
    07/11/2022
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Sonnet BioTherapeutics Holdings, Inc. (SONN) can hold. Click on Rating Page for detail.

The price of Sonnet BioTherapeutics Holdings, Inc. (SONN) is 1.54 and it was updated on 2022-10-06 13:00:30.

Currently Sonnet BioTherapeutics Holdings, Inc. (SONN) is in undervalued.

News
    
News

Hot Penny Stocks to Buy in Mid-June 2022? 3 to Watch

  • Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in Mid-June 2022?
    Thu, Jun. 09, 2022

Trending Penny Stocks to Buy This Month? 3 to Watch in April

  • Can these penny stocks continue to climb this month? The post Trending Penny Stocks to Buy This Month?
    Sun, Apr. 17, 2022

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

  • Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
    Wed, Apr. 13, 2022

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate

  • The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ: SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology.  Sonnet will.
    Wed, Mar. 16, 2022

Trading Penny Stocks? Top Stock Market News for March 16th, 2022

  • What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
    Wed, Mar. 16, 2022
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Sonnet BioTherapeutics (SONN) Stock: Why The Price Fell

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell by 4.57% in the most recent trading session. This is why it happened.
  • 02/09/2022

Top Penny Stocks to Buy This Week? 3 You Need to Watch

  • With October off to a great start for penny stocks, which small-caps are you watching? The post Top Penny Stocks to Buy This Week?
  • 10/04/2021

Penny Stocks That Will Explode? Check These 3 Out For Your List

  • Check these three penny stocks out for your September watchlist The post Penny Stocks That Will Explode? Check These 3 Out For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/15/2021

SONN Stock: Why It Significantly Increased Today

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 20% pre-market. This is why it happened.
  • 09/15/2021

Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September

  • Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?
  • 09/03/2021

See Why Sonnet BioTherapeutics Stock Is Skyrocketing In Premarket Tuesday

  • ​​​​​Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the Company's Fully Human Albumin Binding (FHAB) platform.
  • 08/31/2021

SONN Stock: Over 60% Increase Pre-Market Explanation

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 60% pre-market. This is why it happened.
  • 08/31/2021

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

  • SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset was performed with input from Sonnet's Scientific Advisory Board An IND submission for SON-1410 is anticipated during the second half of 2022 PRINCETON, NJ / ACCESSWIRE / August 30, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform.
  • 08/30/2021

Sonnet BioTherapeutics Stock Slumps After $30M Equity Raise

  • Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) priced the underwritten public offering of 35.3 million shares (including pre-funded warrants) and warrants to purchase up to 35.3 million shares.  Each share of common stock (or pre-funded warrant) has a combined price of $0.85, raising approximately $30.0 million gross proceeds.
  • 08/20/2021

Sonnet BioTherapeutics Shares Fall Over 45% Pre-Market: Why It Happened

  • The shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell over 45% pre-market. This is why it happened.
  • 08/20/2021

Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering

  • PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $0.85, for total gross proceeds of approximately $30.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet.
  • 08/19/2021

Buying Penny Stocks Right Now? 3 to Watch in 2021

  • Looking to buy penny stocks in 2021? Check these 3 out for your list The post Buying Penny Stocks Right Now?
  • 08/19/2021

SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today

  • Sonnet BioTherapeutics (SONN) stock is taking off on Thursday and investors can thank retail traders on social media for pumping it higher. The post SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today appeared first on InvestorPlace.
  • 08/19/2021

Sonnet BioTherapeutics Shares Increase Over 200% Pre-Market: Why It Happened

  • The shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 200% pre-market. This is why it happened.
  • 08/19/2021

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

  • Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Expanded F H AB Intellectual Property Portfolio  Completed $15.9 million At-The-Market Financing  SON-1010 and SON-080 on track for IND submissions by calendar year end  PRINCETON, NJ / ACCESSWIRE / August 16, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th , 2021 and provided a business update. "Throughout the quarter, we've continued to make several advancements towards the clinic with our proprietary Fully Human Albumin Binding (F H AB) pipeline assets, and our partnered product" commented Pankaj Mohan, Ph.D.
  • 08/16/2021

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting

  • Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has changed the date of its upcoming annual meeting of stockholders (the "Annual Meeting") called for the purpose of approving certain proposals, including the election of directors and the ratification of the appointment of Sonnet's independent auditing firm for the fiscal year ended September 30, 2021, from June 24, 2021 to Thursday July 15, 2021 at 9:00 a.m.
  • 06/14/2021

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

  • U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 06/08/2021

SONN Stock: Over 6% Increase Pre-Market Explanation

  • The stock price of Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) increased by over 6% pre-market. This is why it happened.
  • 05/10/2021

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

  • The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome. Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life around 40 hours in NHP.
  • 05/10/2021

SONN Stock: From $2.37 To $2.57 (8.44% Increase) Pre-Market Explanation

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN) increased from $2.37 to $2.57 (up 8.44%) pre-market. This is why it happened.
  • 05/03/2021

3 Penny Stocks With Huge Potential in May 2021

  • Penny stocks are back and better than ever; should you watch these 3 in May? The post 3 Penny Stocks With Huge Potential in May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 05/03/2021

Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics

  • New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone payments totaling up to $21 Million with up to 30% royalties on commercial sales NLT to fund Phase 1b/2a clinical trial and submit an IND planned for the second half of 2021 PRINCETON, NJ / ACCESSWIRE / May 3, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has executed a definitive agreement with New Life Therapeutics Pte. Ltd. (NLT ) of Singapore for the license of low-dose Interleukin 6, or IL-6, for the treatment of Diabetic Peripheral Neuropathy (DPN).
  • 05/03/2021

Hot Penny Stocks To Buy on Robinhood? Here's 4 To Watch

  • Top penny stocks on Robinhood? Here's 4 to check out for your May watchlist The post Hot Penny Stocks To Buy on Robinhood?
  • 04/30/2021

Sonnet BioTherapeutics Provides 2021 Business Update

  • PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs. "Last year we continued execution across our pipeline, and I am excited to share an update on our ongoing activities," commented Pankaj Mohan, Ph.D.
  • 03/29/2021

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

  • PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021.
  • 03/22/2021

2 Falling Knives to Catch

  • Wall Street recommends buying shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) and Sigma Labs Inc. (NASDAQ:SGLB), which you would not expect after these 2 stocks performed so poorly over the prior 52 weeks through Friday, and lost more than 59%. As a result of the sharp decline in the share price, these stocks are known as "falling knives.
  • 12/21/2020
Unlock
SONN Ratings Summary
SONN Quant Ranking